DUONEN multicenter study - personalized PRRT treatment with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with neuroendocrine tumors based on individual dosimetry

Opalińska, Marta; Kamiński, Grzegorz; Dedecjus, Marek; Kowalska, Aldona; Kołodziej, Małgorzata; Saracyn, Marek; Garnuszek, Piotr; Lenda-Tracz, Wioletta; Borkowska, Anna; Gąsior-Perczak, Danuta; Budzyńska, Anna; Kubik, Agata; Kacperski, Krzysztof; Szubstarska, Patrycja; Chalewska, Wioletta; Długosińska, Joanna; Januszkiewicz-Caulier, Joanna; Hubalewska‐Dydejczyk, Alicja; Mikołajczak, Renata

doi:10.1530/endoabs.90.p440

EJEA

2023

DOI: 10.1530/endoabs.90.p440

|View full text |Cite

DUONEN multicenter study - personalized PRRT treatment with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with neuroendocrine tumors based on individual dosimetry

Marta Opalińska¹,

Grzegorz Kamiński²,

Marek Dedecjus³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Individual dosimetry and monitoring response to treatment in tandem PRRT with [¹⁷⁷Lu/⁹⁰Y]-DOTA-TATE

Kacperski,

Budzyńska,

Kubik

et al. 2024

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

Introduction: The Duonen project aims to test the efficacy of tandem PRRT therapy of neuroendocrine tumors with DOTA-TATE labeled with 177Lu and 90Y radionuclides compared to conventional mono-radionuclide therapy using 177Lu with a fixed activity of 7.4 GBq. The paper presents the dosimetric procedure used and preliminary results obtained from the treatment of 40 patients and 113 cycles of therapy. Material and Methods: Dosimetry is performed using the QDose program based on 4 SPECT/CT scans and 5 blood samples taken for bone marrow dosimetry. Calculation of the dose to the kidneys is done by segmenting them on images, fitting the corresponding activity versus time (TAC) curves and calculating the dose using the Voxel-S method. The dose to the red marrow is calculated based on the IDAC2 model using the TAC curve for blood obtained from the measurements (self-dose) and the segmented organs from images (cross-dose). In addition, the time-integrated activity coefficients of activity in selected tumors or high uptake areas in four consecutive cycles of therapy were calculated for several patients as a measure of response to therapy. Results: Large variability of individual doses to kidneys is observed. The average specific dose for 177Lu was equal to 0.76 Gy/GBq, SD = 0.29 Gy/GBq, and for 90Y: 3.26 Gy/GBq, SD = 1.26 Gy/GBq. With the standard activity equal to 7.4 GBq in the first cycle, the activity in the next cycle could be increased by > 10% in 60% of cases and had to be decreased in 16% of cases. Conclusion: Individual dosimetry is an important part of PRRT, leading to significant dose modifications in subsequent cycles in more than 80% of the cases studied.

show abstract

Individual dosimetry and monitoring response to treatment in tandem PRRT with [¹⁷⁷Lu/⁹⁰Y]-DOTA-TATE

Kacperski,

Budzyńska,

Kubik

et al. 2024

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

DUONEN multicenter study - personalized PRRT treatment with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with neuroendocrine tumors based on individual dosimetry

Cited by 1 publication

References 0 publications

Individual dosimetry and monitoring response to treatment in tandem PRRT with [¹⁷⁷Lu/⁹⁰Y]-DOTA-TATE

Individual dosimetry and monitoring response to treatment in tandem PRRT with [¹⁷⁷Lu/⁹⁰Y]-DOTA-TATE

Contact Info

Product

Resources

About

DUONEN multicenter study - personalized PRRT treatment with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with neuroendocrine tumors based on individual dosimetry

Cited by 1 publication

References 0 publications

Individual dosimetry and monitoring response to treatment in tandem PRRT with [177Lu/90Y]-DOTA-TATE

Individual dosimetry and monitoring response to treatment in tandem PRRT with [177Lu/90Y]-DOTA-TATE

Contact Info

Product

Resources

About

Individual dosimetry and monitoring response to treatment in tandem PRRT with [¹⁷⁷Lu/⁹⁰Y]-DOTA-TATE

Individual dosimetry and monitoring response to treatment in tandem PRRT with [¹⁷⁷Lu/⁹⁰Y]-DOTA-TATE